Testing a new radioactive drug for HER2-positive advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new radioactive drug, [177Lu]Lu-ABY-271, to see how safe it is and where it goes in the body. It is for people with HER2-positive breast cancer that has spread and cannot be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer has spread to other parts of the body (metastatic) and cannot be removed with surgery.
- Your cancer must be HER2-positive (a type of protein on the cancer cells) based on a biopsy done in the last 2 years.
- You need at least one tumor that is 15 mm or larger (about the size of a pea or bigger).
- You should be able to care for yourself and be up and about more than half the day (ECOG score 0 to 2).
- If you have brain metastases, they must not be active (causing symptoms or needing treatment right now).
- You cannot have had any other experimental treatment within a certain time before starting this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
This trial tests a new radioactive drug (177Lu-AB-3PRGD2) that targets a protein called integrin αvβ3 found on many solid tumors. It is for people whose cancer has not responded to or has come back after several standard treatments.
This trial tests a radioactive drug (lutetium-177) that targets the HER2 protein, which is found on some cancer cells. It's for people with advanced, HER2-positive or HER2-low solid tumors that haven't responded to other treatments.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.